Anti-ACE2 (NT)
| Code | Size | Price |
|---|
| LEI-A316-20ug | 20 ug | £199.00 |
Quantity:
| LEI-A316-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species:
- Human
- Mouse
- Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
Anti-ACE2 antibody was raised against a peptide corresponding to 14 amino acids near the amino terminus of human ACE2. The immunogen is located within the first 50 amino acids of ACE2.
Long Description:
Angiotensin I converting enzyme 2 (ACE2) is an exopeptidase that catalyses the conversion of angiotensin I to the nonapeptide angiotensin, or the conversion of angiotensin II to angiotensin. ACE 2 has direct effects on cardiac function, and is expressed predominantly in vascular endothelial cells of the heart and the kidneys. ACE2 plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling Pulmonary Hypertension (PH). ACE2 may also have clinical potential as a novel molecular target for the treatment of pancreatic ductal adenocarcinoma (PDAC).
Target:
ACE2
References
1. Acton, S. et al. (2000) Circ Res. 87: E1 2. Gamliel-Lazarovich, A. et al. (2007) Cardiovasc Res. 73: 463 3. Nabel, EG. et al. (2000) N Engl J Med. 347: 1795 4. Raizada, MK. et al. (2009) Am J Respir Crit Care Med. 179(11):1048-54. 5. Yuan, Y. et al. (2009) Tohoku J Exp Med. 217: 123
Related Products
| Product Name | Product Code | Supplier | Anti-ACE2 (CT) | LEI-A313 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-ACE2 (17aa - Intermediate Domain) | LEI-A314 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-ACE2 (Intermediate Domain) | LEI-A315 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||